Create a Free Seeking Alpha Account
Sitewide sale! Get access to our Top Stocks for H2 2025 Event on June 17 by signing up to any Seeking Alpha service with 20% off your first year.
or
By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy
CRDL:CA Cardiol Therapeutics Inc.Stock Price & Overview
Stock Price & Overview
$1.95
CRDL:CA Stock Price
CRDL:CA News
Latest Headlines
Ratings Summary
People Also Follow
Similar to CRDL:CA
ETFs Holding CRDL:CA
CRDL:CA Company Profile
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.